COVID-19 Research Studies
SARS-CoV-2 Infection/Covid-19 and Anosmia – Prevalence Study, Molecular Analysis
and Clinical Trial
Researchers at University College London, led by Professor Valerie J. Lund, CBE and Mr Matt Lechner, and in close collaboration with Professor Carl Philpott from the University of East Anglia, have begun a multi-centre clinical trial investigating the loss of the sense of smell in COVID-19 patients.
The study aims to determine the prevalence of this symptom in those who have experienced the COVID-19 infection, the extent of smell loss and related smell and taste dysfunction, as well as the impact of the symptom on daily life. The study also consists of a randomised controlled trial for eligible participants, which is investigating the potential for smell training as treatment.
Ultimately, the researchers hope to utilise this study to gain a better understanding of the impact of smell loss in COVID-19 patients and inform the way in which we manage this in the future.
This study is now closed. Thank you to everyone that has contributed. Updates on the outcomes of this study will be made available on the research page.
Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection (ODYSSI)
The ODYSSI Mulit-Centre Study (Cambridge, Cornwall and Imperial Hospital London) is recruiting participants who have lost their sense of smell as a result of COVID-19 and have had a positive PCR swab test in the previous 2 weeks. It is a study investigating, measuring and charting the natural history of smell loss in Covid-19 patients and the impact on their daily life.
- Patients who are presenting to hospital with symptoms of SARS CoV-2 infection.
- Patients who go on to develop a positive SARS CoV-2 test.
- Adult patients aged 18 years – 85 years who can give valid written informed consent
- Patients who cannot give a valid written informed consent.
- Patients with negative SARS CoV-2 tests.
- Patients with nasal pathologies like severe deviated nasal septum, nasal masses, head trauma or previously known chronic rhinosinusitis with polyps or on medication for more than 6 months/year for at least one year for chronic rhinosinusitis.
- Patients with any diagnosed neurological disease known to affect olfactory function will be excluded from the study.
This study is now closed. Thank you to everyone that has contributed. Updates and outcomes will be made available on the research page.